Page number 3
2 Investor presentation First nine months of 2023 Agend A a genda Progr Comm Innov Finan
Page number 4
Novo Nordisk ® ress on Strategic Aspirations 2025 mercial execution vation and therapeutic focus ncials






2 Investor presentation First nine months of 2023 Agend A a genda Progr Comm Innov Finan
Novo Nordisk ® ress on Strategic Aspirations 2025 mercial execution vation and therapeutic focus ncials